Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 2 (2005), Issue 3 (March)

1. Detection of B-RAF and N-RAS mutations in human melanoma.
   J Am Coll Surg, 200(3): 362-70. [Abstract] [Full-text]
2. Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas.
   Eur J Cancer, 41(4): 531-8. [Abstract] [Full-text]
3. High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1alpha and basic fibroblast growth factor-mediated mechanisms.
   J Invest Dermatol, 124(3): 638-43. [Abstract] [Full-text]
4. Quantification of melanoma micrometastases in sentinel lymph nodes using real-time RT-PCR.
   J Invest Dermatol, 124(3): 633-7. [Abstract] [Full-text]
5. Diagnostic applicability of in vivo confocal laser scanning microscopy in melanocytic skin tumors.
   J Invest Dermatol, 124(3): 493-8. [Abstract] [Full-text]
6. UV exposure, genetic targets in melanocytic tumors and transgenic mouse models.
   Photochem Photobiol, 81(1): 52-64. [Abstract] [Full-text]
7. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution.
   Pediatrics, 115(3): 649-54. [Abstract] [Full-text]
8. A case of double cancer involving oral malignant melanoma and gastrointestinal stromal tumor (GIST).
   Int J Oral Maxillofac Surg, 34(3): 328-30. [Abstract] [Full-text]
9. In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma.
   Eur J Radiol, 53(3): 506-13. [Abstract] [Full-text]
10. Invasive and noninvasive uveal melanomas have different adhesive properties.
    Eye, 19(3): 342-8. [Abstract] [Full-text]
11. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.
    Clin Cancer Res, 11(4): 1512-20. [Abstract] [Full-text]
12. Pathologic assessment of melanoma sentinel nodes: a role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA.
    Clin Cancer Res, 11(4): 1425-33. [Abstract] [Full-text]
13. Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma.
    Ophthalmology, 112(3): 505-10. [Abstract] [Full-text]
14. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection.
    Nat Med, 11(3): 346-52. [Abstract] [Full-text]
15. Local control of primary oropharyngeal malignant melanomas with limited tissue excision: a report of three cases.
    Eur Arch Otorhinolaryngol, 262(2): 89-92. [Abstract] [Full-text]
16. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta.
    Cancer Immunol Immunother, 54(5): 446-52. [Abstract] [Full-text]
17. Hydroxytyrosol, a natural antioxidant from olive oil, prevents protein damage induced by long-wave ultraviolet radiation in melanoma cells.
    Free Radic Biol Med, 38(7): 908-19. [Abstract] [Full-text]
18. The novel tumor suppressor p33ING2 enhances UVB-induced apoptosis in human melanoma cells.
    Exp Cell Res, 304(2): 531-43. [Abstract] [Full-text]
19. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).
    Cancer Immunol Immunother, 54(5): 453-67. [Abstract] [Full-text]
20. In vivo anti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin-2 cDNA.
    J Gene Med, 7(2): 189-97. [Abstract] [Full-text]
21. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
    Cancer Res, 65(5): 2009-17. [Abstract] [Full-text]
22. Bcl-2 overexpression enhances tumor-specific T-cell survival.
    Cancer Res, 65(5): 2001-8. [Abstract] [Full-text]
23. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells.
    Cancer Res, 65(5): 1800-7. [Abstract] [Full-text]
24. Livedo reticularis associated with interferon alpha therapy in two melanoma patients.
    J Eur Acad Dermatol Venereol, 19(2): 252-4. [Abstract] [Full-text]
25. Malignant melanoma in pregnancy. A population-based evaluation.
    Cancer, 103(6): 1217-26. [Abstract] [Full-text]
26. Urethral advancement procedure for reconstruction after excision of male parameatal melanoma in situ.
    Urol Int, 74(2): 183-4. [Abstract] [Full-text]
27. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Clin Cancer Res, 11(5): 1990-8. [Abstract] [Full-text]
28. NBS1 expression as a prognostic marker in uveal melanoma.
    Clin Cancer Res, 11(5): 1849-53. [Abstract] [Full-text]
29. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
    Clin Cancer Res, 11(5): 1835-41. [Abstract] [Full-text]
30. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results.
    Vaccine, 23(17): 2367-73. [Abstract] [Full-text]
31. Radiofrequency ablation for tumor-related massive hematuria.
    J Vasc Interv Radiol, 16(3): 417-21. [Abstract] [Full-text]
32. Full thickness skin graft for nail unit reconstruction.
    J Hand Surg [Br], 30(2): 194-8. [Abstract] [Full-text]
33. Inhibition of melanoma inhibitory activity (MIA) expression in melanoma cells leads to molecular and phenotypic changes.
    Pigment Cell Res, 18(2): 92-101. [Abstract] [Full-text]
34. A simple calibration method for 106Ru-106Rh eye applicators.
    Radiother Oncol, 74(3): 293-9. [Abstract] [Full-text]
35. PEG-appended beta-(1-->3)-D-glucan schizophyllan to deliver antisense-oligonucleotides with avoiding lysosomal degradation.
    Biomaterials, 26(23): 4866-73. [Abstract] [Full-text]
36. Metastatic uveal melanoma.
    Ophthalmol Clin North Am, 18(1): 143-50, ix. [Abstract] [Full-text]
37. Uveal melanoma: resection techniques.
    Ophthalmol Clin North Am, 18(1): 119-28, ix. [Abstract] [Full-text]
38. Uveal melanoma: proton beam irradiation.
    Ophthalmol Clin North Am, 18(1): 111-8, ix. [Abstract] [Full-text]
39. Infrared thermotherapy: from laboratory to clinic.
    Ophthalmol Clin North Am, 18(1): 99-110, viii-ix. [Abstract] [Full-text]
40. Uveal melanoma: genetic aspects.
    Ophthalmol Clin North Am, 18(1): 85-97, viii. [Abstract] [Full-text]
41. Uveal melanoma: epidemiologic aspects.
    Ophthalmol Clin North Am, 18(1): 75-84, viii. [Abstract] [Full-text]
42. Melanocytic conjunctival tumors.
    Ophthalmol Clin North Am, 18(1): 15-24, vii. [Abstract] [Full-text]
43. Uveal melanocytomas: genetic comparison with uveal and dermal melanomas.
    Arch Ophthalmol, 123(3): 377-80. [Abstract] [Full-text]
44. Tanning beds, sunlamps, and risk of cutaneous malignant melanoma.
    Cancer Epidemiol Biomarkers Prev, 14(3): 562-6. [Abstract] [Full-text]
45. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma.
    J Cutan Pathol, 32(4): 268-73. [Abstract] [Full-text]
46. Personality and disease outcome in malignant melanoma.
    J Psychosom Res, 58(1): 19-27. [Abstract] [Full-text]
47. Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin.
    Head Neck, 27(4): 326-32. [Abstract] [Full-text]
48. Antitumor effects of human ribonuclease inhibitor gene transfected on B16 melanoma cells.
    Int J Biochem Cell Biol, 37(6): 1219-31. [Abstract] [Full-text]
49. Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase D-mitogen-activated protein kinase signaling.
    J Biol Chem, 280(12): 10938-44. [Abstract] [Full-text]
50. Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients.
    Int J Cancer, 114(6): 936-41. [Abstract] [Full-text]
51. V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential.
    Int J Cancer, 114(6): 879-86. [Abstract] [Full-text]
52. In vivo assessment of melanocytic nests in nevi and melanomas by reflectance confocal microscopy.
    Mod Pathol, 18(4): 469-74. [Abstract] [Full-text]
53. Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma.
    Mod Pathol, 18(4): 565-72. [Abstract] [Full-text]
54. Ezrin in primary cutaneous melanoma.
    Mod Pathol, 18(4): 503-10. [Abstract] [Full-text]
55. Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine.
    Cancer Res, 65(6): 2449-56. [Abstract] [Full-text]
56. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Cancer Res, 65(6): 2412-21. [Abstract] [Full-text]
57. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products.
    Cancer Res, 65(6): 2387-96. [Abstract] [Full-text]
58. Hair follicle-derived blood vessels vascularize tumors in skin and are inhibited by Doxorubicin.
    Cancer Res, 65(6): 2337-43. [Abstract] [Full-text]
59. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas.
    Cancer Res, 65(6): 2260-8. [Abstract] [Full-text]
60. Role of matrix metalloproteinases in melanoma cell invasion.
    Biochimie, 87(3): 307-14. [Abstract] [Full-text]
61. The role of B-RAF in melanoma.
    Cancer Metastasis Rev, 24(1): 165-83. [Abstract] [Full-text]
62. Malignant melanoma in a candidate for heart transplantation.
    Dermatology, 210(3): 233-6. [Abstract] [Full-text]
63. Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
    Br J Cancer, 92(6): 1006-12. [Abstract] [Full-text]
64. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Clin Cancer Res, 11(6): 2416-26. [Abstract] [Full-text]
65. Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi--results from the NYU-LCMN registry.
    Br J Dermatol, 152(3): 512-7. [Abstract] [Full-text]
66. Predictions of skin cancer incidence in the Netherlands up to 2015.
    Br J Dermatol, 152(3): 481-8. [Abstract] [Full-text]
67. Analysis of T-cell receptor V beta gene repertoires after immune stimulation and in malignancy by use of padlock probes and microarrays.
    Clin Chem, 51(4): 768-75. [Abstract] [Full-text]
68. Intervention in context-sensitive probabilistic Boolean networks.
    Bioinformatics, 21(7): 1211-8. [Abstract] [Full-text]
69. Histological features used in the diagnosis of melanoma are frequently found in benign melanocytic naevi.
    J Clin Pathol, 58(4): 409-12. [Abstract] [Full-text]
70. Genomic instability in radial growth phase melanoma cell lines after ultraviolet irradiation.
    J Clin Pathol, 58(4): 389-96. [Abstract] [Full-text]
71. Selection for TRAIL resistance results in melanoma cells with high proliferative potential.
    FEBS Lett, 579(9): 1940-4. [Abstract] [Full-text]
72. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.
    Int J Cancer, 115(1): 65-73. [Abstract] [Full-text]
73. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells.
    Int J Cancer, 115(1): 164-9. [Abstract] [Full-text]
74. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy.
    Pediatr Blood Cancer, 44(5): 441-8. [Abstract] [Full-text]
75. Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques.
    J Chromatogr B Analyt Technol Biomed Life Sci, 819(1): 59-66. [Abstract] [Full-text]
76. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
    J Clin Oncol, 23(10): 2346-57. [Abstract] [Full-text]
77. Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion.
    Neoplasia, 7(3): 253-62. [Abstract] [Full-text]
78. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    Int J Cancer, 115(2): 248-55. [Abstract] [Full-text]
79. DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis.
    Int J Cancer, 115(2): 224-30. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.